Literature DB >> 17087859

Management of hypertension and dyslipidemia.

Keith C Ferdinand1, Myra A Kleinpeter.   

Abstract

Cardiovascular disease, the leading cause of death in the United States and other developed societies, can be managed with intensive risk factor modification, including treatment of hypertension and dyslipidemia. Evidence for reduction of cardiovascular morbidity and mortality is summarized in evidence-based guidelines, primarily for hypertension in the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure and for dyslipidemia in the Third Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Many medications exist for treatment of hypertension and a limited number for dyslipidemia; the cornerstone of therapy for both remains lifestyle modification, including dietary interventions. Despite guidelines, control rates of concomitant hypertension and dyslipidemia remain low. Patient adherence may affect achievement of recommended goals of therapy for dyslipidemia and hypertension. Effective education and communication may improve overall achievement of treatment goals.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17087859     DOI: 10.1007/s11906-006-0028-5

Source DB:  PubMed          Journal:  Curr Hypertens Rep        ISSN: 1522-6417            Impact factor:   5.369


  38 in total

1.  A rationale for combination therapy in risk factor management: a mechanistic perspective.

Authors:  R Preston Mason
Journal:  Am J Med       Date:  2005-12       Impact factor: 4.965

2.  Compliance--and improving it--in hypertension.

Authors:  William J Elliott
Journal:  Manag Care       Date:  2003-08

Review 3.  Metabolic syndrome--a new world-wide definition. A Consensus Statement from the International Diabetes Federation.

Authors:  K G M M Alberti; P Zimmet; J Shaw
Journal:  Diabet Med       Date:  2006-05       Impact factor: 4.359

4.  Rationale, design, methods and baseline demography of participants of the Anglo-Scandinavian Cardiac Outcomes Trial. ASCOT investigators.

Authors:  P S Sever; B Dahlöf; N R Poulter; H Wedel; G Beevers; M Caulfield; R Collins; S E Kjeldsen; G T McInnes; J Mehlsen; M Nieminen; E O'Brien; J Ostergren
Journal:  J Hypertens       Date:  2001-06       Impact factor: 4.844

5.  Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group.

Authors: 
Journal:  JAMA       Date:  1991-06-26       Impact factor: 56.272

6.  Prevalence of heart disease and stroke risk factors in persons with prehypertension in the United States, 1999-2000.

Authors:  Kurt J Greenlund; Janet B Croft; George A Mensah
Journal:  Arch Intern Med       Date:  2004-10-25

7.  Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial.

Authors:  George L Bakris; Vivian Fonseca; Richard E Katholi; Janet B McGill; Franz H Messerli; Robert A Phillips; Philip Raskin; Jackson T Wright; Rosemary Oakes; Mary Ann Lukas; Karen M Anderson; David S H Bell
Journal:  JAMA       Date:  2004-11-10       Impact factor: 56.272

8.  Comparison of efficacy and safety of rosuvastatin versus atorvastatin in African-American patients in a six-week trial.

Authors:  Keith C Ferdinand; Luther T Clark; Karol E Watson; Ryan C Neal; Clinton D Brown; B Waine Kong; Boisey O Barnes; William R Cox; Franklin J Zieve; Jonathan Isaacsohn; Joseph Ycas; Philip T Sager; Alex Gold
Journal:  Am J Cardiol       Date:  2005-11-28       Impact factor: 2.778

9.  Feasibility of treating prehypertension with an angiotensin-receptor blocker.

Authors:  Stevo Julius; Shawna D Nesbitt; Brent M Egan; Michael A Weber; Eric L Michelson; Niko Kaciroti; Henry R Black; Richard H Grimm; Franz H Messerli; Suzanne Oparil; M Anthony Schork
Journal:  N Engl J Med       Date:  2006-03-14       Impact factor: 91.245

10.  Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until 1 March 2003.

Authors:  Jan A Staessen; Ji-Guang Wang; Lutgarde Thijs
Journal:  J Hypertens       Date:  2003-06       Impact factor: 4.844

View more
  3 in total

1.  Association of statin therapy with blood pressure control in hypertensive hypercholesterolemic outpatients in clinical practice.

Authors:  Manuel Morgado; Sandra Rolo; Ana Filipa Macedo; Miguel Castelo-Branco
Journal:  J Cardiovasc Dis Res       Date:  2011-01

2.  Apolipoprotein B Levels Predict Future Development of Hypertension Independent of Visceral Adiposity and Insulin Sensitivity.

Authors:  Seung Jin Han; Wilfred Y Fujimoto; Steven E Kahn; Donna L Leonetti; Edward J Boyko
Journal:  Endocrinol Metab (Seoul)       Date:  2020-06-24

3.  Blood pressure and lipid goal attainment in the hypertensive population in the primary care setting in Spain.

Authors:  Vivencio Barrios; Carlos Escobar; Alberto Calderón; José L Llisterri; Rocio Echarri; Eduardo Alegría; Javier Muñiz; Arantxa Matalí
Journal:  J Clin Hypertens (Greenwich)       Date:  2007-05       Impact factor: 3.738

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.